Conolidine’s analgesic results stem from its conversation with non-opioid pain pathways. Contrary to opioids, which bind to µ-opioid receptors within the central anxious system, conolidine modulates alternate molecular targets. A Science Innovations review found that conolidine interacts With all the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://stephenbihdc.dbblog.net/11596102/new-step-by-step-map-for-conolidin-to-replace-traditional-painkillers